[Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

Department of Hematology, Peace Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China. E-mail:

Published: April 2016

Acute myeloid leukemia (AML) is a malignant clonal hematologic disease from hematopoietic stem and progenitor cells. The isocitrate dehychogenase 2 (IDH2) gene mutation has been recently found, which may be associated with the course of AML. The incidence of IDH2 gene mutation in the patients with acute myeloid leukemia is high, especially in the AML patients with normal karyotype. Different subtypes of IDH2 mutation, or companing other molecular biology, will make different influence on clinical features and progress of patients with AML. IDH2 mutation is stable, which can be used as the test sign of AML and minimal residual disease (MRD), and for guiding the clinical treatment and predicting the progress. In this article, the research progress of IDH2 mutation in acute myeloid leukemia is reviewed.

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2016.02.061DOI Listing

Publication Analysis

Top Keywords

acute myeloid
16
idh2 gene
12
gene mutation
12
myeloid leukemia
12
idh2 mutation
12
mutation acute
8
idh2
6
mutation
6
aml
5
[research advances
4

Similar Publications

Adolescent and young adult (AYA) survivors of acute lymphoblastic or myeloid leukemia diagnosed between the ages of 15 and 39 years are at risk for adverse late health effects following cancer treatment and require ongoing survivorship care. This study aims to understand the landscape of transitioning AYAs with leukemia from active treatment to survivorship care. A cross-sectional, anonymous online survey was sent out via listserv/email.

View Article and Find Full Text PDF

Unlabelled: Biochemical analyses of cerebrospinal fluid (CSF) are routinely performed at diagnosis in many pediatric oncology and hematology centers when acute leukemia is diagnosed. However, the clinical relevance of these analyses remains unclear. We conducted a retrospective analysis of biochemical CSF data from children diagnosed with acute leukemia at two French hospitals between 2016 and 2023 assessing the results in relation to the presence or absence of leukemic neuromeningeal involvement and the correlation between cytological and biochemical analyses.

View Article and Find Full Text PDF

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

View Article and Find Full Text PDF

LncRNA HOXA10-AS as a novel biomarker and therapeutic target in human cancers.

Front Mol Biosci

January 2025

Department of Immunology, School of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, Shandong, China.

Long non-coding RNAs (lncRNAs) are crucial regulatory molecules that participate in numerous cellular development processes, and they have gathered much interest recently. HOXA10 antisense RNA (HOXA10-AS, also known as HOXA-AS4) is a novel lncRNA that was identified to be dysregulated in some prevalent malignancies. In this review, the clinical significance of HOXA10-AS for the prognosis of various cancers is analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!